Pfizer's CEO said the company could make 'tremendous investments' in the US if Trump's tariffs go away
1. Pfizer's CEO cites tariffs hindering major US investments. 2. Albert Bourla anticipates 'tremendous investments' in R&D if tariffs are clarified. 3. Trump's potential pharmaceutical tariffs may affect Pfizer's manufacturing strategy. 4. Pfizer estimates current tariffs could cost $150 million by 2025. 5. Competitors like AstraZeneca consider shifting US manufacturing due to tariff fears.